Interventional AI-Human Collaboration for Steatotic Liver Disease Screening
China7,969 participantsStarted 2026-02-24
Plain-language summary
Steatotic liver disease (SLD) is one of the most prevalent chronic liver diseases worldwide, affecting nearly 30% of the global population and projected to exceed 55% by 2040. Timely identification and management of intermediate- and high-risk SLD patients are essential, yet early detection remains challenging because current diagnostic modalities, such as biopsy, ultrasonography, and serum indices, are invasive, insensitive, operator-dependent, or difficult to scale. In contrast, non-contrast CT is widely available in routine care and offers substantial potential for opportunistic SLD screening, although this value has not been fully utilized. Our previously developed MAOSS model accurately identifies intermediate- and high-risk individuals, with MAOSS score≥1.6 combined with Fibro Score ≥1.7, demonstrating high sensitivity and specificity in our large-scale retrospective study. However, despite these promising retrospective findings, the model has not undergone prospective interventional validation, and it remains unclear whether an AI-guided workflow can truly enhance clinical risk stratification, diagnostic yield, and downstream management in real-world SLD populations. Therefore, a prospective intervention study is needed to determine whether MAOSS-guided identification and recall of at-risk individuals can meaningfully improve fibrosis detection and optimize clinical care pathways for SLD.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged ≥18 years undergoing routine non-contrast or contrast-enhanced chest or abdominal CT examination.
* CT images with adequate hepatic coverage and sufficient image quality for MAOSS analysis.
* Willing to undergo the recall evaluation and either: having a FIB-4 result within the past 1 month, or willing to complete blood testing (ALT, AST, platelet count) required for FIB-4 calculation and undergo FibroScan or MRE assessment.
* Willing to participate in the study and able to provide written informed consent at the time of recall.
Exclusion Criteria:
* Known malignant liver tumors (e.g., HCC, cholangiocarcinoma) or a history of liver transplantation or major hepatic resection.
* Known cirrhosis based on noninvasive fibrosis assessment tests, liver biopsy or complications of decompensated disease, or with a documented history of cirrhosis identified by clinical notes will be excluded.
* Biliary obstruction, acute cholangitis, or other conditions that may interfere with interpretation of liver biochemistry or fibrosis risk assessment.
* CT images with severe artifacts or incomplete liver coverage preventing reliable MAOSS analysis.
* Severe acute systemic illness (e.g., sepsis, shock, acute heart failure), or pregnancy or breastfeeding.
* Unwilling or unable to complete recall procedures, including required blood tests, FibroScan, or MRE when indicated, or unable to comply with study follow-up.
* Severe comorbidity with an expected survival of …
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Effective referral yield for escalated hepatology care